Lilly obesity pill Foundayo records 7,335 prescriptions
Eli Lilly weight-loss drug Foundayo saw 7,335 U.S. prescriptions in its fourth week. Analysts say the pill needs 22,000 weekly scripts to meet sales targets.
Xurve View
Insights:
Xurve View
ELI LILLY & CO recorded 7,335 prescriptions for its oral weight-loss drug Foundayo in the United States during its fourth week. The uptake lags behind the Wegovy pill from Novo Nordisk, which launched in January with a first-mover advantage. Investors view these oral treatments as expanding the weight-loss market to millions of patients, potentially countering pricing pressure on injectable treatments.
